International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients

被引:93
作者
Voves, Claudia
Wuillemin, Walter A. [1 ]
Zeerleder, Sacha
机构
[1] Kantonsspital, Dept Internal Med, Div Hematol, CH-6000 Luzern 16, Switzerland
[2] Kantonsspital, Cent Hematol Lab, Luzern 16, Switzerland
[3] Univ Bern, Inselspital, Cent Hematol Lab, CH-3010 Bern, Switzerland
[4] CLB, Sanquin Blood Supply Fdn, Amsterdam, Netherlands
[5] Inselspital Bern, Dept Hematol, Bern, Switzerland
关键词
disseminated intravascular coagulation; International Society on Thrombosis and Haemostasis; sepsis; multiple organ dysfunction syndrome;
D O I
10.1097/01.mbc.0000240916.63521.2e
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated the score for disseminated intravascular coagulation (DIC) recently published by the International Society for Thrombosis and Haemostasis (ISTH) in a well-defined series of sepsis patients. Thirty-two patients suffering from severe sepsis and eight patients with septic shock were evaluated following the ISTH DIC score. Fibrin monomer and D-dimer were chosen as fibrin-related markers (FRM), respectively. DIC scores for nonsurvivors (n = 13) as well as for septic shock patients were higher (P < 0.04) compared with survivors and patients with severe sepsis, respectively. Using fibrin monomer and D-dimer, 30 and 25% of patients suffered from overt DIC. Overt DIC was associated with significantly elevated thrombin-antithrombin complexes and plasminogen activator inhibitor type-1 levels as well as with significantly lower factor VII clotting activity. Patients with overt DIC had a significantly higher risk of death and of developing septic shock. Since more than 95% of the sepsis patients had elevated FRIVI, the DIC score was strongly dependent on prolongation of the prothrombin time and platelet counts. The ISTH DIC score is useful to identify patients with coagulation activation, predicting fatality and disease severity. It mainly depends on the prolongation of the prothrombin time and platelet counts.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 26 条
[1]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[2]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[3]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[4]   C1-inhibitor in patients with severe sepsis and septic shock:: Beneficial effect on renal dysfunction [J].
Caliezi, C ;
Zeerleder, S ;
Redondo, M ;
Regli, B ;
Rothen, HU ;
Zürcher-Zenklusen, R ;
Rieben, R ;
Devay, J ;
Hack, CE ;
Lämmle, B ;
Wuillemin, WA .
CRITICAL CARE MEDICINE, 2002, 30 (08) :1722-1728
[5]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[6]  
DEBOER JP, 1993, CIRC SHOCK, V39, P59
[7]   Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score [J].
Dempfle, CE ;
Wurst, M ;
Smolinski, M ;
Lorenz, S ;
Osika, A ;
Olenik, D ;
Fiedler, F ;
Borggrefe, M .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (04) :812-818
[8]   Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation [J].
Dhainaut, JF ;
Yan, SB ;
Joyce, DE ;
Pettilä, V ;
Basson, B ;
Brandt, JT ;
Sundin, DP ;
Levi, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) :1924-1933
[9]   Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients [J].
Gando, S ;
Wada, H ;
Asakura, H ;
Iba, T ;
Eguchi, Y ;
Okamoto, K ;
Ohtomo, Y ;
Kawasugi, K ;
Koga, S ;
Koseki, A ;
Tsuji, H ;
Mayumi, T ;
Murata, A ;
Nakagawa, M .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2005, 11 (01) :71-76
[10]  
Gando S, 1996, THROMB HAEMOSTASIS, V75, P224